45329
2016
2016
eng
14
18
article
BioMed Central
London
1
--
--
--
Antiphospholipid antibodies detected by line immunoassay differentiate among patients with antiphospholipid syndrome, with infections and asymptomatic carriers
Background: Antiphospholipid antibodies (aPL) can be detected in asymptomatic carriers and infectious patients. The aim was to investigate whether a novel line immunoassay (LIA) differentiates between antiphospholipid syndrome (APS) and asymptomatic aPL+ carriers or patients with infectious diseases (infectious diseases controls (IDC)). Methods: Sixty-one patients with APS (56 primary, 22/56 with obstetric events only, and 5 secondary), 146 controls including 24 aPL+ asymptomatic carriers and 73 IDC were tested on a novel hydrophobic solid phase coated with cardiolipin (CL), phosphatic acid, phosphatidylcholine, phosphatidylethanolamine, phosphatidylglycerol, phosphatidylinositol, phosphatidylserine, beta2-glycoprotein I (beta 2GPI), prothrombin, and annexin V. Samples were also tested by anti-CL and anti-beta 2GPI ELISAs and for lupus anticoagulant activity. Human monoclonal antibodies (humoAbs) against human beta 2GPI or PL alone were tested on the same LIA substrates in the absence or presence of human serum, purified human beta 2GPI or after CL-micelle absorption. Results: Comparison of LIA with the aPL-classification assays revealed good agreement for IgG/IgM a beta 2GPI and aCL. Anti-CL and anti-beta 2GPI IgG/IgM reactivity assessed by LIA was significantly higher in patients with APS versus healthy controls and IDCs, as detected by ELISA. IgG binding to CL and beta 2GPI in the LIA was significantly lower in aPL+ carriers and Venereal Disease Research Laboratory test (VDRL) + samples than in patients with APS. HumoAb against domain 1 recognized beta 2GPI bound to the LIA-matrix and in anionic phospholipid (PL) complexes. Absorption with CL micelles abolished the reactivity of a PL-specific humoAb but did not affect the binding of anti-beta 2GPI humoAbs. Conclusions: The LIA and ELISA have good agreement in detecting aPL in APS, but the LIA differentiates patients with APS from infectious patients and asymptomatic carriers, likely through the exposure of domain 1.
IEEE transactions on geoscience and remote sensing
10.1186/s13075-016-1018-x
27209064
1478-6354
1478-6362
wos2016:2019
111
WOS:000376372300001
Roggenbuck, D (reprint author), Brandenburg Univ Technol Cottbus Senftenberg, Inst Biotechnol, Fac 2, Grossenhainer Str 57, D-01968 Senftenberg, Germany.; Roggenbuck, D (reprint author), Medipan GmbH, Res & Dev Dept, Dahlewitz Berlin, Germany., dirk.roggenbuck@b-tu.de
Inova Diagnostics; IRCCS Istituto Auxologico Italiano
importub
2020-03-22T17:38:01+00:00
filename=package.tar
1594b870823ad371688c628f3a62518f
Dirk Roggenbuck
Maria Orietta Borghi
Valentina Somma
Thomas Buettner
Peter Schierack
Katja Hanack
Claudia Grossi
Caterina Bodio
Paolo Macor
Philipp von Landenberg
Francesco Boccellato
Michael Mahler
Pier Luigi Meroni
eng
uncontrolled
Antiphospholipid syndrome
eng
uncontrolled
Antiphospholipid antibody
eng
uncontrolled
Phospholipid binding proteins
eng
uncontrolled
Beta2-glycoprotein I
eng
uncontrolled
Line immunoassay
Institut für Biochemie und Biologie
Referiert
Import
40721
2016
2018
eng
14
436
postprint
1
2018-06-18
2018-06-18
--
Antiphospholipid antibodies detected by line immunoassay differentiate among patients with antiphospholipid syndrome, with infections and asymptomatic carriers
Background
Antiphospholipid antibodies (aPL) can be detected in asymptomatic carriers and infectious patients. The aim was to investigate whether a novel line immunoassay (LIA) differentiates between antiphospholipid syndrome (APS) and asymptomatic aPL+ carriers or patients with infectious diseases (infectious diseases controls (IDC)).
Methods
Sixty-one patients with APS (56 primary, 22/56 with obstetric events only, and 5 secondary), 146 controls including 24 aPL+ asymptomatic carriers and 73 IDC were tested on a novel hydrophobic solid phase coated with cardiolipin (CL), phosphatic acid, phosphatidylcholine, phosphatidylethanolamine, phosphatidylglycerol, phosphatidylinositol, phosphatidylserine, beta2-glycoprotein I (β2GPI), prothrombin, and annexin V. Samples were also tested by anti-CL and anti-β2GPI ELISAs and for lupus anticoagulant activity. Human monoclonal antibodies (humoAbs) against human β2GPI or PL alone were tested on the same LIA substrates in the absence or presence of human serum, purified human β2GPI or after CL-micelle absorption.
Results
Comparison of LIA with the aPL-classification assays revealed good agreement for IgG/IgM aß2GPI and aCL. Anti-CL and anti-ß2GPI IgG/IgM reactivity assessed by LIA was significantly higher in patients with APS versus healthy controls and IDCs, as detected by ELISA. IgG binding to CL and ß2GPI in the LIA was significantly lower in aPL+ carriers and Venereal Disease Research Laboratory test (VDRL) + samples than in patients with APS. HumoAb against domain 1 recognized β2GPI bound to the LIA-matrix and in anionic phospholipid (PL) complexes. Absorption with CL micelles abolished the reactivity of a PL-specific humoAb but did not affect the binding of anti-β2GPI humoAbs.
Conclusions
The LIA and ELISA have good agreement in detecting aPL in APS, but the LIA differentiates patients with APS from infectious patients and asymptomatic carriers, likely through the exposure of domain 1.
Postprints der Universität Potsdam Mathematisch-Naturwissenschaftliche Reihe
urn:nbn:de:kobv:517-opus4-407211
1866-8372
online registration
Arthritis Research & Therapy 18 (2016) ; DOI: 10.1186/s13075-016-1018-x
CC-BY - Namensnennung 4.0 International
Dirk Roggenbuck
Maria Orietta Borghi
Valentina Somma
Thomas Büttner
Peter Schierack
Katja Hanack
Claudia Grossi
Caterina Bodio
Paolo Macor
Philipp von Landenberg
Francesco Boccellato
Michael Mahler
Pier Luigi Meroni
Zweitveröffentlichungen der Universität Potsdam : Mathematisch-Naturwissenschaftliche Reihe
436
eng
uncontrolled
Antiphospholipid syndrome
eng
uncontrolled
Antiphospholipid antibody
eng
uncontrolled
Phospholipid binding proteins
eng
uncontrolled
Beta2 - glycoprotein I
eng
uncontrolled
Line immunoassay
Medizin und Gesundheit
open_access
Mathematisch-Naturwissenschaftliche Fakultät
Institut für Biochemie und Biologie
Referiert
Open Access
BioMed Central
Universität Potsdam
https://publishup.uni-potsdam.de/files/40721/pmnr_436.online.pdf